News
News Home
Quick Bites
Exploradio
News Archive
News Channel
Special Features
NPR
nowplaying
On AirNewsClassical
Loading...
  
School Closings
WKSU Support
Funding for WKSU is made possible in part through support from the following businesses and organizations.

NOCHE

Akron General

Metro RTA


For more information on how your company or organization can support WKSU, download the WKSU Media Kit.

(WKSU Media Kit PDF icon )


Donate Your Vehicle to WKSU

Programs Schedule Make A Pledge Member BenefitsFAQ/HelpContact Us
Health and Medicine


Change in FDA policy fast tracks testing of Alzheimer's drug
But other scientists are unable to reproduce dramatic improvements shown in preliminary tests in Cleveland
by WKSU's JEFF ST. CLAIR


Reporter / Host
Jeff St. Clair
 
Dr. Gary Landeth (right) hopes to prove that Bexarotene can treat Alzheimer’s disease through phase 1 clinical trials. He and then graduate student Paige Cramer started a company called Rexceptor to develop the drug for clinical use.
Courtesy of Jeff St.Clair
Download (WKSU Only)
In The Region:

A promising new treatment for Alzheimer’s disease developed in Cleveland has run into some roadblocks, but backers of a repurposed drug are moving forward with clinical trials.

LISTEN: ST.CLAIR ON ALZHEIMER'S DRUG

Other options:
Windows Media / MP3 Download (1:04)


The drug Bexarotene was originally used to treat skin cancer. But Gary Landreth, a neuroscientist at Case Western Reserve University, showed last year that mice bred to have Alzheimer’s disease dramatically improved when given the drug. Now Landreth is ready to test it on people.

He says a recent change in FDA policy allows the drug to be tested on healthy people to determine whether it reduces soluble amyloid beta proteins that are believed to lead to Alzheimer’s.

“The FDA has recognized we now need to treat people who are at risk of Alzheimer’s disease but are cognitively normal, and that changes everything,” Landreth says.

The scientific community, however, is not convinced the drug actually works. Last week, the journal "Science" published independent studies that failed to reproduce Landreth’s dramatic results. However, he says he is still holding out hope his original findings in mice will be validated.

“Proving this mechanism in humans is essential to any subsequent development of the drug,” Landreth says.

Landreth says he could know by the end of the year whether Bexarotene will move on to further testing or join the dozens of other would-be Alzheimer treatments littering the path to a cure.

Listener Comments:

Does anyone have any idea as to what dosage they will be testing?


Posted by: DICKY_DOOO on May 28, 2013 4:05AM
Add Your Comment
Name:

Location:

E-mail: (not published, only used to contact you about your comment)


Comments:




 
Page Options

Print this page

E-Mail this page / Send mp3

Share on Facebook




Stories with Recent Comments

Ohio lawmakers propose grants for home construction for disabled people
We have been trying to have a "Visitability Bill" passed for years. Thanks, Greg

Lake County crimes may give Trump immigration fodder
Shoddy reporting at best. "Mixed views" The question that came to my mind was, "How many people did he have to interview to get "mixed views". Do the two peo...

Ohio's U.S. Sen. Sherrod Brown announces plans to improve Medicare by lowering prescription costs for seniors
Sounds good. I'm living in Florida to escape the snow. So far it's working. I retired from GM in 2000. Keep pushing for all the working people. In the long run ...

The tiny town that time, and elections, forgot may go out of existence
Thank you for this story. I grew up in Limaville, my parents home is there still...unsellable due to the septic/sewer problem. Sometimes I am sorry I left...wis...

Where Ohio'sJohn Kasich stands in the presidential polls
We are fans of Gov. Kasich since he served in the House of Representatives. It pleases us to finally see him as the potential President of the United States. We...

Cleveland hosts the first national Movement for Black Lives conference
What a wonderful experience this was, So much love and understanding, without all of the other distractions that tend to come with organizing for change, this e...

Air Force unit gets training and Youngstown gets rid of some eyesores
Do they have to totally destroy all the beautiful oak and leaded windows, which I am thinking are probably there? Do they just have to destroy them like that? C...

Jewish challah and Native American fry bread at an Akron cultural exchange
Each time I saw the young students relate to each other, I got goose bumps. These young students can and hopefully will teach all of us to live and respect eac...

One of the Cleveland Orchestra's most celebrated musicians bids farewell
I had the honor of studying with Franklin Cohen in the late 80s and early 90s. He is unparalleled both as a clarinetist and as a musician. His deep personal war...

Summa's dress code is not 'etched in stone'
SOME OF THESE POLICIES ARE A COMPLETE JOKE. UNLESS YOU ARE DOING THESE TYPE OF JOBS EVERY DAY, YOU DON'T KNOW WHAT IS COMFORTABLE AND REASONABLE OR NOT. UNLESS ...

Copyright © 2015 WKSU Public Radio, All Rights Reserved.

 
In Partnership With:

NPR PRI Kent State University

listen in windows media format listen in realplayer format Car Talk Hosts: Tom & Ray Magliozzi Fresh Air Host: Terry Gross A Service of Kent State University 89.7 WKSU | NPR.Classical.Other smart stuff. NPR Senior Correspondent: Noah Adams Living on Earth Host: Steve Curwood 89.7 WKSU | NPR.Classical.Other smart stuff. A Service of Kent State University